Alterations in systemic complement component 3a and 5a levels in patients with cerebral arteriovenous malformations

Journal of Clinical Neuroscience

Volumn 18, Issue 9, 2011, Pages 1235-1239

  Haque, Raqeeb ^a   Hwang, Brian Y ^a   Appelboom, Geoffrey ^a   Piazza, Matthew A ^a   Guo, Kuanghua ^a   Connolly, E Sander ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Activation; C3a; C5a; Cerebral arteriovenous malformation; Complement cascade; Component protein; Inflammation

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BRAIN ARTERIOVENOUS MALFORMATION; BRAIN SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; MICROSURGERY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THERAPY EFFECT; TREATMENT RESPONSE;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; COMPLEMENT C3A; COMPLEMENT C5A; FEMALE; HUMANS; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 79961010742     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2011.02.015     Document Type: Article

References (26)

1. Kim H, Pawlikowska L, Chen Y, et al. Brain arteriovenous malformation biology relevant to hemorrhage and implication for therapeutic development. Stroke 2009;40(3 Suppl.):S95-97.
2. Young WL, Yang GY. Are there genetic influences on sporadic brain arteriovenous malformations? Stroke 2004;35(11 Suppl. 1):2740-5.
3. Chen Y, Zhu W, Bollen AW, et al. Evidence of inflammatory cell involvement in brain arteriovenous malformations. Neurosurgery 2008;62:1340-9, discussion 1349-1350.
4. Leblanc GG, Golanov E, Awad IA, et al. Biology of vascular malformations of the brain. Stroke 2009;40:e694-702.
5. Pawlikowska L, Tran MN, Achrol AS, et al. Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. Stroke 2004;35:2294-300.
6. Storer KP, Tu J, Karunanayaka A, et al. Inflammatory molecule expression in cerebral arteriovenous malformations. J Clin Neurosci 2008;15:179-84. (Pubitemid 350298904)
7. Achrol AS, Kim H, Pawlikowska L, et al. Association of tumor necrosis factor-alpha-238G>A and apolipoprotein E2 polymorphisms with intracranial hemorrhage after brain arteriovenous malformation treatment. Neurosurgery 2007;61:731-9, discussion 740.
8. Achrol AS, Pawlikowska L, McCulloch CE, et al. Tumor necrosis factor-alpha-238G>A promoter polymorphism is associated with increased risk of new hemorrhage in the natural course of patients with brain arteriovenous malformations. Stroke 2006;37:231-4. (Pubitemid 43732078)
9. Kim H, Marchuk DA, Pawlikowska L, et al. Genetic considerations relevant to intracranial hemorrhage and brain arteriovenous malformations. Acta Neurochir Suppl 2008;105:199-206.
10. Tu J, Stoodley MA, Morgan MK, et al. Responses of arteriovenous malformations to radiosurgery: ultrastructural changes. Neurosurgery 2006;58:749-58, discussion 749-758.
11. Ducruet AF, Zacharia BE, Hickman ZL, et al. The complement cascade as a therapeutic target in intracerebral hemorrhage. Exp Neurol 2009;219:398-403.
12. Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery 2003;53:123-33, discussion 133-125.
13. Lindsberg PJ, Ohman J, Lehto T, et al. Complement activation in the central nervous system following blood-brain barrier damage in man. Ann Neurol 1996;40:587-96. (Pubitemid 26357883)
14. Mack WJ, Ducruet AF, Hickman ZL, et al. Early plasma complement C3a levels correlate with functional outcome after aneurysmal subarachnoid hemorrhage. Neurosurgery 2007;61:255-60, discussion 260-251.
15. Machalinska A, Dziedziejko V, Mozolewska-Piotrowska K, et al. Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration. Ophthalmic Res 2009;42:54-9.
16. Mocco J, Wilson DA, Komotar RJ, et al. Alterations in plasma complement levels after human ischemic stroke. Neurosurgery 2006;59:28-33, discussion 28-33.
17. Reynolds R, Hartnett ME, Atkinson JP, et al. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 2009;50:5818-27.
18. Starke RM, Komotar RJ, Hwang BY, et al. Systemic expression of matrix metalloproteinase-9 in patients with cerebral arteriovenous malformations. Neurosurgery 2010;66:343-8, discussion 348.
19. Kao WJ, Sapatnekar S, Hiltner A, et al. Complement-mediated leukocyte adhesion on poly(etherurethane ureas) under shear stress in vitro. J Biomed Mater Res 1996;32:99-109. (Pubitemid 26272346)
20. Yin W, Ghebrehiwet B, Weksler B, et al. Classical pathway complement activation on human endothelial cells. Mol Immunol 2007;44:2228-34. (Pubitemid 46097113)
21. Gasque P, Ischenko A, Legoedec J, et al. Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells. J Biol Chem 1993;268:25068-74. (Pubitemid 23335530)
22. Thomas A, Gasque P, Vaudry D, et al. Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol 2000;12:1015-23. (Pubitemid 30599354)
23. DiScipio RG, Daffern PJ, Jagels MA, et al. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 1999;162:1127-36. (Pubitemid 29035444)
24. Schraufstatter IU, Trieu K, Sikora L, et al. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 2002;169:2102-10. (Pubitemid 34857676)
25. Aronowski J, Hall CE. New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. Neurol Res 2005;27:268-79. (Pubitemid 40523798)
26. Wang J, Dore S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 2007;27:894-908. (Pubitemid 46659028)